Chronic Heart Failure
Conditions
Keywords
chronic heart failure, neuregulin, mortality
Brief summary
The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure subjects with baseline NT-proBNP level between 600 pg/ml and 1700 pg/mL and NYHA class II to III.
Detailed description
The mortality of chronic heart failure patients remains high, in spite of current treatment. RhNRG-1(recombinant human neuregulin-1)directly work on the cardiomyocyte and restored the normal structure and function of it. Both the preclinical trials, phase II clinical trials and already completed phase III clinical trails have confirmed that rhNRG-1 effectively enhance the heart function, reverse the remodeling of left ventricular, and reduce all-cause mortality in heart failure animals and humans. More importantly, rhNRG-1 can significantly reduce the mortality of heart failure subjects with baseline NT-proBNP level ≤1600 fmol/mL and NYHA class II to III. In this phase III study, the investigators will further confirm the efficacy of rhNRG-1 in reducing the death rate of heart failure subjects with baseline NT-proBNP level between 600 pg/ml and 1700 pg/mL and NYHA class II to III.
Interventions
DRUGrhNRG-1
10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
DRUGPlacebo
10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
Sponsors
Zensun Sci. & Tech. Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Age between 18 and 75, gender balance (no more than 960 subjects of either gender in total 1600 subjects). * 2\. Left ventricular ejection fraction (LVEF)≤40% (ECHO). * 3\. Subjects with chronic heart failure (NYHA class II OR III ). * 4\. 600 pg/ml ≤NT-proBNP≤1700 pg/ml ( by Roche assay Kit in central lab). * 5\. Diagnosed as chronic systolic heart failure (history, symptoms, signs), and in stable condition in the last one month. * 6\. Receiving standard therapy for chronic heart failure, reach target dose or max tolerable dose for one month, or has not changed the dose for one month before randomization. * 7\. Capable of signing the informed consent form.
Exclusion criteria
* 1\. New chronic heart failure patients, or patients receiving standard therapy on chronic heart failure for less than 3 months. * 2\. NYHA functional class I OR IV. * 3\. NT-proBNP \< 600 pg/ml OR NT-proBNP\>1700 pg/ml (by Roche assay Kit in central lab). * 4\. Patients with hypertrophic cardiomyopathy, rheumatic heart disease, constrictive pericarditis, significant valvular pathological change or congenital heart diseases, primary or secondary severe pulmonary artery hypertension. * 5\. Ischemic heart failure without recanalization or with recanalization in recent six months. * 6\. Acute MI in the last 3 months. * 7\. Unstable angina. * 8\. Patients with acute pulmonary edema or acute hemodynamic disorder. * 9\. Chronic heart failure patients with acute hemodynamic disorder or acute decompensation in the last 1 month (symptoms and signs suggest worsening chronic heart failure and may require intravenous drug therapy). * 10\. Patients with right heart failure caused by pulmonary disease. * 11\. Patients diagnosed with pericardial effusion (\>50 ml) or pleural effusion(\>200 ml), or evidenced by Echocardiogram. * 12\. Cardiac surgery or cerebrovascular accident within recent six months. * 13\. Preparing for heart transplantation or CRT, or has received CRT. * 14\. Serious ventricular arrhythmia (sustained ventricular tachycardia or frequent paroxysmal ventricular tachycardia). * 15.Diagnosis of perinatal or chemotherapy-induced cardiomyopathy in last 12 months. * 16\. Serious hepatic or renal dysfunction (bilirubin 1.5 times above the normal upper limit, AST or ALT 2 times above the normal upper limit, serum creatinine\>2.0mg/dL, HBV or HCV positive). * 17\. Serum potassium \<3.2 mmol/L or \>5.5 mmol/L. * 18\. Systolic blood pressure \<90mmHg or \>160mmHg. * 19\. Women of childbearing age who have a pregnancy plan within 2 years (women of childbearing age are defined as women who have a pregnancy physiology). * 20\. Pregnant or lactating women. * 21\. Patients who participated in any clinical trial in the recent three months. * 22\. Subject with a life expectancy less than 6 months as assessed by the investigator. * 23\. Serious nervous system diseases (Alzheimer's disease, advanced Parkinsonism),lower limb defects, or deaf-mute. * 24\. History of any malignancy or suffering from cancer, or biopsy proven pre-malignant condition (e.g., DICS or cervical atypia). * 25\. Evidence (physical examination, chest X-ray (CXR), ECHO or other tests) shows some active malignancy or adenoidal hypertrophy or neoplasm that has an effect on heart function or the endocrine system, e.g., pheochromocytoma or hyperthyroidism (Thyroid nodules with normal thyroid function do not need to be excluded). * 26\. As judged by the investigator that the subject cannot complete the study or adhere to the study requirements (due to the management reasons or others).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All-cause mortality | 1 year | Including deaths from cardiovascular and non-cardiovascular causes, Log-Rank test was used for comparison between groups, and Kaplan-Meier survival curves were plotted; COX proportional hazard model was used to estimate the HR and its 95% confidence interval. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| All-cause mortality of female subjects | 1 year | Log-Rank test was used for comparison between groups, and Kaplan-Meier survival curves were plotted; COX proportional hazard model was used to estimate the HR and its 95% confidence interval. |
| All-cause mortality of male subjects | 1 year | Log-Rank test was used for comparison between groups, and Kaplan-Meier survival curves were plotted; COX proportional hazard model was used to estimate the HR and its 95% confidence interval. |
| Percentage of all-cause re-hospitalization | 1 year | The Kaplan-Meier curve was used to describe the cumulative incidence rate of the first re-hospitalization, and the differences between the two groups were compared using Log-Rank. |
| Mortality caused by cardiovascular events | 1 year | Log-Rank test was used for comparison between groups, and Kaplan-Meier survival curves were plotted; COX proportional hazard model was used to estimate the HR and its 95% confidence interval. |
| Change of NT-proBNP level at the 25th week and 52th week | 1 year | The paired t test or signed rank sum test was used to compare the changes before and after treatment in each group, and the comparison between groups was performed by analysis of variance or Wilcoxon rank sum test. |
| New York Heart Association (NYHA) functional classification | 1 year | For the NYHA cardiac functional grading after administration, summarize the number and percentage of subjects by different study visit period, compare the efficacy differences among test groups and control groups. In addition, calculate the changes of NYHA cardiac functional grade from baseline of the subjects. The intragroup changes will be analyzed by signed-rank sum test, intergroup comparison will be conducted by Wilcoxon test. |
| Percentage of Participants with re-hospitalization caused by worsening heart failure | 1 year | The Kaplan-Meier curve was used to describe the cumulative incidence rate of the first re-hospitalization, and the differences between the two groups were compared using Log-Rank. |
Countries
China
Contacts
Primary ContactXiaorui Wang, Ph.D
Backup ContactRunlin Gao, Ph.D,MD
Outcome results
None listed